What is already known about this subject:
- A complete consensus has not yet been reached on the effect of
angiotensin-converting enzyme inhibitors and angiotensin receptor
blockers on the COVID-19 clinical course.
- Metformin and insulin are associated with better and poor COVID-19
clinical course, respectively.
- There are inconclusive results about calcium-channel blockers on
COVID-19 clinical course.